OCRA

What OCRA does

Ovarian Cancer Research Alliance (OCRA) is a 501(c)(3) nonprofit headquartered in New York (45 Rockefeller Plaza, 20th Floor) with a Washington DC advocacy office, formed in 2019 through the merger of the Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance. The organization funds and promotes research, advocacy, and patient support across ovarian and broader gynecologic cancers, having cumulatively invested $140 million in research and helped secure more than $3.8 billion in federal funding through advocacy. Its programs serve approximately 140,000 patients, families, and community members annually.

OCRA's core platform is the Community Accelerated Research Exchange ("Research Exchange"), a global AI-powered ecosystem launched in May 2026 and built on AWS infrastructure using Amazon Bedrock and Amazon SageMaker. The platform comprises three components: Living Lab, a privacy-protected patient registry currently with 451 participants capturing patient-reported outcomes, quality of life, and financial impacts; Discovery Lab, a Trusted Research Environment (SOC 2 Type II, NIST 800-171, HIPAA Eligible) hosting 89 datasets and 2,787 newly indexed studies monthly; and Research Pulse, an AI-curated weekly feed of gynecologic oncology literature. In parallel, OCRA operates the ROCCA Platform, a federated international data network for rare ovarian cancer research with steering committee members including MD Anderson, Peter MacCallum Cancer Centre, Cedars-Sinai, UBC, and UNSW Sydney.

OCRA's revenue model combines individual donations, corporate sponsorships (AbbVie, AstraZeneca, GSK, Genentech, Genmab, Merck, PMV Pharma, Shirley Z. Johnson Trust), federal grant advocacy, and event fundraising (Rivkin Family SummeRun 5K in Seattle). Through the Global Ovarian Cancer Research Consortium — a partnership with Microsoft AI for Good Lab — OCRA awards $1 million AI Accelerator Grants plus Azure compute credits. Patient-facing services are free, while research access and federated data infrastructure are provided to researchers at no cash cost underwritten by OCRA's fundraising base. Leadership is led by President & CEO Audra Moran, recognized as a 2026 Crain's Notable Leader in Health Care.

Name

OCRA

Legal name

Ovarian Cancer Research Alliance, Inc.

Website

https://ocrahope.org

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

11–50 employees

Short description

OCRA is a 501(c)(3) nonprofit that funds ovarian and gynecologic cancer research, advocates for federal and state policy, and supports 140,000 patients annually through its AI-powered Research Exchange platform, Living Lab patient registry, and Discovery Lab research environment.

Ownership category

akta.pro rank

Product category

Cancer Research and Patient Advocacy

NAICS

Voluntary Health Organizations (813212), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Open Courseware & Course Modules (OCW) (EDAGAJAB), Investigator & Site Training / GCP Support (HLAGACAF)

Keywords

• Ovarian cancer research
• Cancer patient support
• Gynecologic cancer advocacy
• Patient registry platform
• Cancer research grants

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Individual Donations: Individual donors contribute through online donations, monthly giving programs, event participation (SummeRun), and fundraising campaigns. Stacey Dickinson's Play the Day business donates 10% of net sales to OCRA.
2. Corporate Sponsorships: Pharmaceutical companies (AbbVie, AstraZeneca, GSK, Genentech) support Living Lab and other programs. Patient support programs are sponsored by AbbVie, AstraZeneca, Genentech, Genmab, GSK, Merck, PMV Pharma, and Shirley Z. Johnson Trust.
3. Federal Research Grants: OCRA advocates for and helps secure federal funding for ovarian and gynecologic cancer research. Has helped secure more than $3.8 billion in federal funding through advocacy efforts.
4. Research Investment: OCRA has invested $140 million toward finding a cure for ovarian and gynecologic cancers through grants to researchers and scientific programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

OCRA is a nonprofit organization that funds ovarian and gynecologic cancer research, provides patient support services, and operates the Research Exchange — an AI-powered ecosystem connecting patients, researchers, and clinicians through a patient registry (Living Lab) and a research collaboration environment (Discovery Lab). The organization has invested $140 million in research and supports 140,000 people annually through patient programs, advocacy, and education.

Product overview

OCRA operates as a nonprofit organization offering a unified product portfolio centered on the Community Accelerated Research Exchange (Research Exchange), a first-of-its-kind AI-powered ecosystem that connects patients, researchers, and clinicians through a unified platform. The Research Exchange encompasses two interconnected modules: Living Lab (a privacy-protected patient registry capturing real-world data including patient-reported outcomes, quality of life, and treatment history) and Discovery Lab (an AI-powered Trusted Research Environment enabling global scientific collaboration with multi-omics, imaging, and clinical data). Research Pulse provides AI-curated weekly summaries of gynecologic research. OCRA also funds the ROCCA Platform for rare ovarian cancer research, offers patient support programs (Woman to Woman Peer Mentor, Free Genetic Testing, Staying Connected Support Series, Clinical Trial Navigator), operates advocacy initiatives through its Center for Public Policy, hosts scientific and patient conferences (Rivkin Symposium, International Gynecologic Cancer Conference), runs the annual SummeRun fundraising event, and awards AI Accelerator Grants through the Global Ovarian Cancer Research Consortium. The organization has invested $140 million toward finding a cure for ovarian and gynecologic cancers and supports 140,000 people annually through its programs.

Differentiator

Problem solved

Functional benefit

Brands

• Research Exchange: A global, AI-powered ecosystem connecting patients, researchers, and clinicians to accelerate gynecologic cancer research. Includes Living Lab (patient registry) and Discovery Lab (research environment).
• Living Lab
• Discovery Lab
• Rivkin Family SummeRun
• Rivkin Ovarian Cancer Research Symposium
• Woman to Woman Peer Mentor Program
• Survivors Teaching Students
• ROCCA Platform

Products and services

• Research Exchange (Community Accelerated Research Exchange) AI-powered ecosystem that transforms gynecologic cancer research by connecting patients, researchers, and clinicians through a unified platform integrating Living Lab (patient registry) and Discovery Lab (AI-enabled research environment).
• Living Lab Privacy-protected patient registry that captures real-world data, giving patients an active role in advancing research while creating a continuously expanding dataset of lived experience, treatment history, and outcomes.
• Discovery Lab AI-powered research environment where scientists can access and analyze shared data, collaborate across institutions, and build upon each other's work within a secure Trusted Research Environment (TRE) featuring multi-omics data, imaging, biospecimen resources, electronic medical records, patient-reported outcomes, and longitudinal follow-up data.
• ROCCA Platform (Rare Ovarian Cancer Collaborative Analytics) International federated data network connecting researchers globally to accelerate breakthroughs in rare ovarian cancer research. Uses federated analysis where each site keeps data secure locally, runs standardized analyses, and only shares summary results with no individual-level data leaving institutions.
• Woman to Woman Peer Mentor Program Peer support program connecting patients and survivors with trained mentors who have experienced gynecologic cancer firsthand.
• Free Genetic Testing Program Program providing free genetic testing to help identify risk for ovarian and gynecologic cancers.
• Staying Connected Support Series Support programming including Roundtables, Workshops, Webinars, and support sessions for patients, survivors, and caregivers.
• Clinical Trial Navigator Resource helping patients understand and navigate clinical trial options.
• Center for Public Policy Initiative to enhance advocacy and policymaking for ovarian and gynecologic cancers, featuring an interactive policy map and continued efforts to secure federal funding and support patients.
• Rivkin Ovarian Cancer Research Symposium Annual scientific symposium bringing together researchers to share findings and advance ovarian cancer research.
• International Gynecologic Cancer Conference Annual free online conference featuring expanded programming for ovarian, endometrial, cervical, and rare gynecologic cancers, with expert presentations and community connection.
• Rivkin Family SummeRun Annual 5K run/walk event held at Seward Park in Seattle, one of the largest ovarian cancer fundraising events in the country, benefiting OCRA's research programs.
• Global Ovarian Cancer Research Consortium AI Accelerator Grants $1 million USD AI Accelerator grants funded by the Global Ovarian Cancer Research Consortium to power AI-driven ovarian cancer research with cloud compute credits.

Quantifiable outcome

• 280+ media mentions reaching 171 million people for Research Exchange launch
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core.

• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 18 May 2026MD Anderson Cancer Center is a member of the ROCCA Steering Committee, contributing expertise in low-grade serous ovarian cancer research through Dr. David Gershenson.
• Peter MacCallum Cancer CentrecoreStrategic or Co-development Partner · 18 May 2026Peter MacCallum Cancer Centre in Australia is a ROCCA Steering Committee member, with Dr. Kylie Gorringe leading mucinous ovarian cancer research within the network.
• UNSW SydneycoreStrategic or Co-development Partner · 18 May 2026UNSW Sydney is a member of the ROCCA Steering Committee for rare ovarian cancer research collaboration.
• Cedars-Sinai Medical CenterscoreStrategic or Co-development Partner · 18 May 2026Cedars-Sinai Medical Centers participates in the ROCCA Steering Committee for international rare ovarian cancer research collaboration.
• University of British ColumbiacoreStrategic or Co-development Partner · 18 May 2026Dr. Aline Talhouk from University of British Columbia serves as ROCCA Coordinating Center Lead, with her work at the intersection of data science and gynecologic health laying the groundwork for ROCCA's federated model.
• Amazon Web Services (AWS)coreTechnology or Integration · 8 May 2026AWS is providing $1 million in cloud compute credits to support the Community Accelerated Research Exchange platform. The platform is built on AWS infrastructure including Amazon Bedrock and Amazon SageMaker. AWS has recognized this work as a model for other diseases, highlighting its potential to demonstrate a new model for how data, technology, and community can come together to accelerate discovery.
• Global Ovarian Cancer Research ConsortiumcoreStrategic or Co-development Partner · 7 May 2026The Consortium, with OCRA as a key member, announced a second $1 million USD AI Accelerator Grant on World Ovarian Cancer Day, with AWS compute support to power research improving ovarian cancer survival rates. 21 international teams competed for the grant.
• Microsoft AI for Good LabcoreTechnology or Integration · 19 February 2026Microsoft's AI for Good Lab is providing up to $1 million in in-kind Azure compute credits for the inaugural AI Accelerator Grant. The grant funds an international research team analyzing large ovarian cancer datasets from the US, UK, Canada, and Australia using AI models to identify patterns linked to survival and treatment response.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• National Comprehensive Cancer Network: Alliance of leading academic cancer centers producing clinical practice guidelines and outcomes research. Adjacent in the cancer research ecosystem; ROCCA steering committee members (MD Anderson, Cedars-Sinai) are NCCN institutions.
• American Cancer Society: Largest US cancer nonprofit with nationwide research, patient support, and advocacy across all cancer types. Competes with OCRA for general donor dollars and federal advocacy attention despite much broader scope.

Direct peers

• Pancreatic Cancer Action Network: Single-disease cancer nonprofit combining research grants, patient services, and federal advocacy. Operates a comparable integrated model to OCRA within a different cancer vertical.
• Cancer Research Institute: Cancer immunology research grantmaking nonprofit with patient education and advocacy. Comparable in research funding focus, though thematically specialized in immuno-oncology rather than gynecologic cancers.
• Prevent Cancer Foundation: Cancer research and education funder supporting early detection and prevention research with associated advocacy. Similar nonprofit structure combining research grants, public education, and federal advocacy.
• National Ovarian Cancer Coalition: Voluntary health organization singularly focused on ovarian cancer, providing patient education, support, and advocacy. Mirrors OCRA's ovarian-specific mission and competing for similar donor and sponsor dollars.
• Stand Up To Cancer: Multi-institution translational cancer research funding collaborative with entertainment-industry fundraising. Comparable in funding model (high-profile donor-backed grants, team-science approach) and cancer research focus.
• Susan G. Komen: Disease-specific breast cancer nonprofit combining research funding, patient support, advocacy, and community events at national scale. Closest structural analogue to OCRA's integrated research/advocacy/support model.
• LUNGevity Foundation: Leading lung cancer-specific nonprofit funding research, running patient support programs, and driving advocacy. Comparable single-disease research/advocacy structure competing for similar federal and pharma funding.
• V Foundation for Cancer Research: Nationally recognized cancer research grant funder supporting investigator-initiated translational and clinical research. Comparable to OCRA in the cancer research grantmaking function, though broader in disease scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ocrahope
• YouTubeyoutube.com/user/TheOCRF
• Facebookfacebook.com/OCRAHOPE
• LinkedInlinkedin.com/company/ocrahope
• Instagraminstagram.com/ocrahope

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OCRA